论文部分内容阅读
目的:探究贝前列腺素钠片联合海昆肾喜胶囊治疗糖尿病肾病的效果。方法:研究选择2015年9月-2017年1月间在我院进行糖尿病肾病治疗的患者96例当做研究对象,用数字法将两组患者分为实验组与对照组,每组48例,实验组患者采用贝前列腺素钠片联合海昆肾喜胶囊治疗,对照组患者单独使用海昆肾喜胶囊治疗,观察两组患者治疗前后尿蛋白定量、尿素氮(BUN)以及血肌酐(Scr)。结果:治疗前,实验组各项指标与对照组相比,差异不具有统计学意义(P>0.05),治疗后,实验组BUN(5.46±0.14)mmol/L、Scr(105.46±15.34)μmol/L、尿蛋白(1.64±0.03)g明显优于对照组[(7.46±0.13)mmol/L、(124.64±15.64)μmol/L、(2.16±0.06)g],(P<0.05)。结论:贝前列腺素钠片联合海昆肾喜胶囊治疗糖尿病肾病效果显著,能够使尿蛋白的尿量减少,能够使肾脏剩余的功能得到保存,应在临床中积极推广。
Objective: To investigate the effect of beraprost sodium tablets combined with Hai Kun Shen Xi Capsule in the treatment of diabetic nephropathy. Methods: Ninety-six patients with diabetic nephropathy who were treated in our hospital from September 2015 to January 2017 were selected as study objects. Two groups of patients were divided into experimental group and control group by digital method, with 48 cases in each group. The patients were treated with beraprost sodium tablets in combination with Haikun Shenxi Capsules. The patients in the control group were treated with Haikun Shenxi Capsules alone. Urine protein, urea nitrogen (BUN) and serum creatinine (Scr) were measured before and after treatment in both groups. Results: Before treatment, there was no significant difference between the experimental group and the control group (P> 0.05). After the treatment, BUN (5.46 ± 0.14) mmol / L and Scr (105.46 ± 15.34) μmol / L, urinary protein (1.64 ± 0.03) g was significantly better than that of the control group [(7.46 ± 0.13) mmol / L, (124.64 ± 15.64) μmol / L, (2.16 ± 0.06) g], P <0.05. Conclusion: Bei prostaglandin sodium tablets combined with Hai Kun Shen Xi capsule treatment of diabetic nephropathy significant effect, can reduce the urine output of urine protein, can make the remaining function of the kidney be preserved, and should be actively promoted in the clinic.